Literature DB >> 22007875

Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study.

Masahito Kawabori1, Satoshi Kuroda, Taku Sugiyama, Masaki Ito, Hideo Shichinohe, Kiyohiro Houkin, Yuji Kuge, Nagara Tamaki.   

Abstract

Recent studies have indicated that bone marrow stromal cells (BMSC) may improve neurological function when transplanted into an animal model of CNS disorders, including cerebral infarct. However, there are few studies that evaluate the therapeutic benefits of intracerebral and intravenous BMSC transplantation for cerebral infarct. This study was aimed to clarify the favorable route of cell delivery for cerebral infarct in rats. The rats were subjected to permanent middle cerebral artery occlusion. The BMSC were labeled with near infrared (NIR)-emitting quantum dots and were transplanted stereotactically (1 × 10⁶ cells) or intravenously (3 × 10⁶ cells) at 7 days after the insult. Using in vivo NIR fluorescence imaging technique, the behaviors of BMSC were serially visualized during 4 weeks after transplantation. Motor function was also assessed. Immunohistochemistry was performed to evaluate the fate of the engrafted BMSC. Intracerebral, but not intravenous, transplantation of BMSC significantly enhanced functional recovery. In vivo NIR fluorescence imaging could clearly visualize their migration toward the cerebral infarct during 4 weeks after transplantation in the intracerebral group, but not in the intravenous, group. The BMSC were widely distributed in the ischemic brain and some of them expressed neural cell markers in the intracerebral group, but not in the intravenous group. These findings strongly suggest that intravenous administration of BMSC has limited effectiveness at clinically relevant timing and intracerebral administration should be chosen for patients with ischemic stroke, although further studies would be warranted to establish the treatment protocol.
© 2011 Japanese Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007875     DOI: 10.1111/j.1440-1789.2011.01260.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  27 in total

Review 1.  Update on therapeutic mechanism for bone marrow stromal cells in ischemic stroke.

Authors:  Huan Wan; Fangqin Li; Lei Zhu; Jing Wang; Zizhen Yang; Yujun Pan
Journal:  J Mol Neurosci       Date:  2013-09-19       Impact factor: 3.444

Review 2.  Personalized nanomedicine advancements for stem cell tracking.

Authors:  Miroslaw Janowski; Jeff W M Bulte; Piotr Walczak
Journal:  Adv Drug Deliv Rev       Date:  2012-07-20       Impact factor: 15.470

Review 3.  Cell based therapies for ischemic stroke: from basic science to bedside.

Authors:  Xinfeng Liu; Ruidong Ye; Tao Yan; Shan Ping Yu; Ling Wei; Gelin Xu; Xinying Fan; Yongjun Jiang; R Anne Stetler; George Liu; Jieli Chen
Journal:  Prog Neurobiol       Date:  2013-12-12       Impact factor: 11.685

4.  Triggering Receptor Expressed on Myeloid Cells-2 Correlates to Hypothermic Neuroprotection in Ischemic Stroke.

Authors:  Masahito Kawabori; Masaaki Hokari; Zhen Zheng; Jong Youl Kim; Cyrus Calosing; Christine L Hsieh; Mary C Nakamura; Midori A Yenari
Journal:  Ther Hypothermia Temp Manag       Date:  2013-12-01       Impact factor: 1.286

5.  Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke.

Authors:  Masahito Kawabori; Rachid Kacimi; Tiina Kauppinen; Cyrus Calosing; Jong Youl Kim; Christine L Hsieh; Mary C Nakamura; Midori A Yenari
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

6.  Intravenous transplantation of amnion-derived mesenchymal stem cells promotes functional recovery and alleviates intestinal dysfunction after spinal cord injury.

Authors:  Soichiro Takamiya; Masahito Kawabori; Kazuyoshi Yamazaki; Sho Yamaguchi; Aki Tanimori; Koji Yamamoto; Shunsuke Ohnishi; Toshitaka Seki; Kotaro Konno; Khin Khin Tha; Daigo Hashimoto; Masahiko Watanabe; Kiyohiro Houkin; Miki Fujimura
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

7.  Platelet lysate and granulocyte-colony stimulating factor serve safe and accelerated expansion of human bone marrow stromal cells for stroke therapy.

Authors:  Tomohiro Yamauchi; Hisayasu Saito; Masaki Ito; Hideo Shichinohe; Kiyohiro Houkin; Satoshi Kuroda
Journal:  Transl Stroke Res       Date:  2014-07-26       Impact factor: 6.829

8.  Effect of cell origin and timing of delivery for stem cell-based bone tissue engineering using biologically functionalized hydrogels.

Authors:  Christopher R Dosier; Brent A Uhrig; Nick J Willett; Laxminarayanan Krishnan; Mon-Tzu Alice Li; Hazel Y Stevens; Zvi Schwartz; Barbara D Boyan; Robert E Guldberg
Journal:  Tissue Eng Part A       Date:  2014-08-19       Impact factor: 3.845

Review 9.  Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke.

Authors:  Mark A Eckert; Quynh Vu; Kate Xie; Jingxia Yu; Wenbin Liao; Steven C Cramer; Weian Zhao
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-12       Impact factor: 6.200

10.  Mesenchymal Stem Cell Sheet Promotes Functional Recovery and Palliates Neuropathic Pain in a Subacute Spinal Cord Injury Model.

Authors:  Kazuyoshi Yamazaki; Masahito Kawabori; Toshitaka Seki; Soichiro Takamiya; Kotaro Konno; Masahiko Watanabe; Kiyohiro Houkin; Miki Fujimura
Journal:  Stem Cells Int       Date:  2021-07-09       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.